Source:http://linkedlifedata.com/resource/umls/id/C0289630
PDQ: A synthetic analog of bradykinin. Lobradimil is a potent, specific bradykinin B-2 receptor agonist that stimulates B-2 receptors expressed on the surface of brain capillary endothelial cells, thereby reversibly increasing the permeability of the blood-brain barrier (BBB). Compared to bradykinin, this agent possesses enhanced receptor selectivity, greater plasma stability, and a longer half-life. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42352&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42352&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1606" NCI Thesaurus),NCI: A substance that is being studied for its ability to help other drugs reach the brain. It belongs to the family of drugs called bradykinin agonists.,NCI: A synthetic analog of bradykinin. Lobradimil is a potent, specific bradykinin B-2 receptor agonist that stimulates